河南陪游女-河南陪游女_主页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
Yantai Dongcheng north pharmaceutical Co., Ltd
Where you are now: home page >> subsidiary >>Yantai Dongcheng north pharmaceutical Co., Ltd

Yantai Dongcheng north pharmaceutical Co., Ltd. was established in February 1993 with a registered capital of 50 million yuan and a planned land area of 300 mu. It has been put into operation for 150 mu. It is a wholly-owned subsidiary of Yantai Dongcheng Pharmaceutical Group Co., Ltd. in May 2012, Yantai Dongcheng Biochemical Co., Ltd. and its subsidiaries were successfully listed on Shenzhen Stock Exchange.

At present, the company mainly produces freeze-dried powder injection (including hormone) and small volume injection. At present, there are 17 varieties and 30 production approval numbers. The main products of the workshop are defibrase for injection, urotropin for injection, chorionic gonadotropin for injection, methionine vitamin B1 for injection, levocarnitine for injection, hydrocortisone sodium succinate for injection, etc.

The company has always put product quality in the first place and attached great importance to the implementation of GMP. The company passed the national GMP certification for many times in 2001, 2005 and 2010. In May 2014, the new plant area of the company successfully passed the new GMP certification. At the same time, organize GMP self inspection and production equipment safety self inspection regularly. The company has established a complete set of management system covering all elements specified in GMP to ensure product quality. In terms of hardware, it is equipped with advanced and complete imported testing instruments, including liquid chromatograph made in the United States, liquid chromatograph and total organic carbon analyzer produced in Japan, domestic advanced gas chromatograph, atomic absorption spectrophotometer, ultraviolet spectrophotometer, moisture detector, and precision electronic balance of Mettler, Switzerland.

 

 

Since its establishment, the company has actively introduced and trained advanced talents, committed to the research of new drugs and focused on the quality of products. The company has a standardized management system, paying five insurances and one fund, paid annual leave, major festival expenses, birthday gifts, supporting transportation and accommodation subsidies and other benefits for employees, and regularly organizes employees to travel and hold various sports and cultural activities, so as to enrich employees' life while working. At present, there are 120 employees, 80% of which are junior college or above. Technical personnel and quality inspection personnel are college degree or above, and have the corresponding technical title, high-quality personnel determine the company's strong strength in technology and quality inspection. Relying on the strength of the R & D center of the group company, the company continuously develops and introduces new products and injects new vitality into the development of the company.

 

 

For the better development of the enterprise, the group company has invested 477 million yuan to build a modern pharmaceutical production plant meeting the new GMP certification. After all of them are put into operation, it is estimated that: (1) the freeze-dried powder injection production line with an annual output of 14.93 million chorionic gonadotropin for injection, 10 million pieces of hydrocortisone sodium succinate for injection, and 1.2 million pieces of urotropin for injection; (2) 30 million pieces of heparin sodium injection, The annual production line of chondroitin sulfate injection and chondroitin sulfate injection with an annual output of 25 million pieces is a water injection injection injection production line; (3) a production line of solid preparation tablets with an annual output of 500 million glucosamine hydrochloride chondroitin sulfate tablets and 125 million pieces of cytochrome c tablets; (4) a production line with an annual output of 200 million capsules of chondroitin sulfate and glucosamine. After the new plant is put into operation, it is estimated that the annual additional operating revenue will reach 1824.05 million yuan.

Up to now, the first phase of the new plant area has been successfully completed as planned. The production area covers an area of 100000 square meters, with a construction area of 32400 square meters, and has passed the national GMP certification. It was officially put into operation in May 2014.

contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1